Acrivon Therapeutics, Inc. cotiza a 1.90 USD y tiene una capitalización bursátil de $81M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), …
| Periodo | 2026-05 | 2026-03 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | $-0.49 | $-0.49 | $-0.47 | — |
| Estimado | $-0.52 | $-0.46 | $-0.58 | $-0.58 |
| Sorpresa | +5.8% | -6.5% | +19.0% | — |
| Métrica | ACRV | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -69.2% | -40.4% | -28.8% |
| ROA | -60.1% | -32.0% | -28.1% |
| Current Ratio | 7.69 | 2.84 | +4.85 |
| Debt / Equity | — | 0.28 | — |